Tetrahydrocurcumin-Peptide
/ Tetrahydrocurcumin-peptide hybrid conjugate (cosmetic)ALIAS · THC-peptide hybrid · Curcumin-peptide complex
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Vendor-marketed conjugate or hybrid pairing tetrahydrocurcumin (a hydrogenated curcumin metabolite with antioxidant activity) with a peptide carrier or active. No identifiable PubMed-indexed primary literature characterising the specific vendor conjugate, its sequence, conjugation chemistry, or topical efficacy versus placebo. Mechanistic claims are inherited by analogy from the parent tetrahydrocurcumin antioxidant literature.
Tetrahydrocurcumin (the hydrogenated reduction product of curcumin) has independent literature as a small-molecule antioxidant and tyrosinase inhibitor with cosmetic relevance for hyperpigmentation and oxidative-stress-related skin endpoints. The peptide-conjugate form is asserted by suppliers to combine that antioxidant activity with a peptide carrier intended to improve skin penetration, stability, or pairing with a separate biological active. The specific conjugation chemistry, peptide sequence, and pharmacology of the vendor-marketed compound have not been described in independent primary literature.
None substantive. The compound is a vendor-marketed conjugate without independent published characterisation. Buyers cannot verify identity, purity, or pharmacology against a published reference standard.
No formal safety database for the conjugate. Tetrahydrocurcumin alone has a moderate cosmetic safety profile in supplier-sponsored work; conjugate-specific safety has not been independently characterised.
Regulatory status
- FDA status:
- Not FDA-approved
Vendor product variation in conjugation chemistry, peptide-to-tetrahydrocurcumin ratio, and free-tetrahydrocurcumin content is unconstrained by any external standard. Inference from free tetrahydrocurcumin literature does not transfer to the conjugate without supporting characterisation.